I don’t have the latest market shares, but the crux of the WSJ piece in #msg-75408172 is that PFE is throwing in the towel (now that the 180-day H-W is ending) and will not seek any new US contracts for branded Lipitor.
Nevertheless, Lipitor will continue to be a $3B+ drug worldwide, IMHO.
Market Data 
Markets 
AI
